Zydus Cadila ties up with Takeda Pharmaceuticals for chikungunya vaccine

chikungunyaZydus Cadila, a global healthcare provider, and Takeda Pharmaceutical Company Limited, one of the world´s largest pharmaceutical companies, announced a partnership to develop vaccine for chikungunya, an emerging infectious disease.

The broadbased agreement includes early stage development to the final commercialisation of the vaccine against chickungunya. There is currently no vaccine to prevent or medicine to treat this virus infection.

“By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all important step to prevent the disease burden which is highly prevalent in developing countries and causes suffering and disability,” said Pankaj R. Patel, Chairman and Managing Director, Zydus group.

Chikungunya has been identified in over 60 countries in Asia, Africa, Europe and the US.

“Our belief is that chikungunya can be prevented by vaccines, and that a vaccine might be licensed more quickly if we can accelerate development with this Zydus partnership,¨ said Dr. Rahul Singhvi, Takeda Vaccines Chief Operating Officer.

Since 2005, India, Indonesia, Maldives, Myanmar and Thailand have reported over 1.9 million cases and almost 1.3 million suspected cases of Chikungunya being recorded in the Caribbean islands, Latin American countries, and the United States of America till 2015.

The chikungunya virus is most often spread to people by Aedes aegypti and Aedes albopictus mosquitoes, the same vectors that spread dengue and zika.

After the bite of an infected mosquito, illness occurs usually between 4 and 8 days but can range from 2 to 12 days. In some people, the joint pain may persist for months.

The most common symptoms of chikungunya virus infection are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, or rash. Outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, chikungunya virus was found for the first time in the Americas on islands in the Caribbean.

People at risk for severe indications include newborns infected around the time of birth, older adults (>65 years), and people with medical conditions such as high blood pressure, diabetes, or heart disease.

Terms of the agreement are not disclosed, but it is expected that this partnership will boost access to medicines in the future through this novel partnership.



Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been terminated.The total investment will be euro 16.875 million, which comes to about...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS primarily develops, manufactures and markets products across various therapeuti...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta tablets of Boehringer Ingelheim Pharmaceuticals, Inc.An Abbreviated New Drug ...
Lupin launches injectable iron formulations in India Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.The product is currently marketed in 33 countries, including 21 European Union coun...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, r...
Aditya Birla´s fashion and retail unit ties up with UK luxury brand Ted Baker Aditya Birla Fashion and Retail Ltd said it entered into agreement with UK based fashion brand Ted Baker.Ted Baker London is a British luxury clothing retail company."We are happy to join hands with Ted Baker and build a strong presence for the brand with Indian consumers. This partnership will enable our consumers to explore to a new world of fashio...
Lypsa Gems to sell via Gitanjali Group’s jewelsouk.com Lypsa Gems and Jewellery Ltd said it tied up with Jewelsouk.com to sell ‘Lypsa Atelier’ branded diamond-studded jewellery.“This tie-up is part of our E-commerce push. Lypsa Atelier is currently available on Flipkart, Snapdeal, Craftsvilla, Shopclues in addition to Jewelsouk.”, said Jeeyan Patwa, Director, Lypsa Gems and Jewellery Ltd.Lypsa plans to s...
Sun Pharma to get dengue vaccine technology from ICGEB Pharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being developed to commercialize in Indian and international markets.A serotype is a...
Aarti Industries to return Rs 96 cr to shareholders via buyback Speciality Chemicals company Aarti Industries Ltd said it will buy back12 lakh equity shares at Rs 800 each, aggregating to Rs 96 cr.The company´s Board of Directors approved the equity shares -- representing up to 1.44% of the company's base."The public announcement setting out the process, timelines and other requisite detail will be released in du...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol Capsules are therapeutically equivalent to the reference l...
India overdependent on China for medicines – study India may have emerged as a key supplier of generic and affordable medicine for the world market, but it has an "overwhelming dependence" on China for the raw material required to produce these drugs, industry association Assocham said.Indian companies depend on China to supply them with the main raw material in drug making -- known as Active Pharmaceuti...
Bajaj Finance to provide auto loans to Baxi drivers Baxi, which operates commercial two wheelers, said it has partnered with Bajaj Finance Limited to finance salaried individuals who want to buy new bikes with the option to operate on a ride share basis.As part of the agreement, Bajaj Finance will provide attractive loans with minimum processing fees, and very low down payment, to salaried individuals who...
US Govt agency to help disburse loans to Indian SMEs RBL Bank and NeoGrowth Credit Pvt will provide loans to small and medium enterprises in the Indian retail segment that are excluded from mainstream funding and financing with the help of a US government agency.The funding will be backed by the Overseas Private Investment Corporation (OPIC) -- a US Government organization that mobilizes private capita...
Lupin licenses taste-masking technology from Monosol for paediatric tablets Pharma Major Lupin Ltd. said its US subsidiary, Lupin Pharmaceutical Inc., has agreed to license technology from Monosol Rx to develop multiple paediatric-focused products.Lupin would develop the pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery technology.MonoSol Rx’s PharmFilm technology is a drug delivery platform tha...
Ruchi Soya to plant oil palm in 25,000 hectares in Arunachal Pradesh Agri and Food FMCG company Ruchi Soya Industries Ltd. said it signed an agreement with the Government of Arunachal Pradesh to boost palm oil production through development of quality palm plantations and human capacity building.With this agreement, Ruchi Soya Industries Limited now has obtained permission for oil palm development in 45,000 hectares, cove...